Literature DB >> 23979730

Iatrogenic Cushing's syndrome induced by posaconazole.

Benoit Pilmis1, Hélène Coignard-Biehler, Vincent Jullien, Olivier Hermine, Philippe Touraine, Marc Lecuit, Olivier Lortholary.   

Abstract

Iatrogenic Cushing's syndrome is an undesirable outcome of glucocorticoids treatment. It can be increased by pharmacologic interactions. Glucocorticoid therapy, given in association with ritonavir, and some azole treatments are causes of iatrogenic Cushing's syndrome. We present a patient with common-variable immunodeficiency who received 7 years of itraconazole therapy for bronchial colonization with Aspergillus in combination with inhaled fluticasone without any Cushingoid symptoms. After a switch to posaconazole, the patient developed Cushingoid symptoms.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23979730      PMCID: PMC3811248          DOI: 10.1128/AAC.00416-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Acute adrenal insufficiency associated with high dose inhaled steroids.

Authors:  J Wong; P Black
Journal:  BMJ       Date:  1992-05-30

2.  Cushing's syndrome without excess cortisol.

Authors:  D R Woods; C S Arun; P A Corris; P Perros
Journal:  BMJ       Date:  2006-02-25

3.  Drug interactions between inhaled corticosteroids and enzymatic inhibitors.

Authors:  Amélie Daveluy; Cécile Raignoux; Ghada Miremont-Salamé; Pierre-Olivier Girodet; Nicholas Moore; Françoise Haramburu; Mathieu Molimard
Journal:  Eur J Clin Pharmacol       Date:  2009-04-28       Impact factor: 2.953

Review 4.  Airway and systemic effects of inhaled corticosteroids in asthma: dose response relationship.

Authors:  B J Lipworth
Journal:  Pulm Pharmacol       Date:  1996-02

5.  Iatrogenic Cushing syndrome due to nasal steroid drops.

Authors:  Veysel Nijat Baş; Semra Cetinkaya; Zehra Aycan
Journal:  Eur J Pediatr       Date:  2011-12-28       Impact factor: 3.183

6.  Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey.

Authors:  A Cornillet; C Camus; S Nimubona; V Gandemer; P Tattevin; C Belleguic; S Chevrier; C Meunier; C Lebert; M Aupée; S Caulet-Maugendre; M Faucheux; B Lelong; E Leray; C Guiguen; J-P Gangneux
Journal:  Clin Infect Dis       Date:  2006-07-27       Impact factor: 9.079

7.  Rapid onset of iatrogenic adrenal insufficiency in a patient with cystic fibrosis-related liver disease treated with inhaled corticosteroids and a moderate CYP3A4 inhibitor.

Authors:  Wynton C Hoover; LaCrecia J Britton; Jay Gardner; Tracy Jackson; Hector Gutierrez
Journal:  Ann Pharmacother       Date:  2011-06-28       Impact factor: 3.154

8.  Ritonavir-fluticasone interaction causing Cushing syndrome in HIV-infected children and adolescents.

Authors:  Renata Arrington-Sanders; Nancy Hutton; George K Siberry
Journal:  Pediatr Infect Dis J       Date:  2006-11       Impact factor: 2.129

Review 9.  Adrenal suppression and Cushing's syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature.

Authors:  M M Foisy; E M K Yakiwchuk; I Chiu; A E Singh
Journal:  HIV Med       Date:  2008-05-04       Impact factor: 3.180

10.  Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study.

Authors:  D Wexler; R Courtney; W Richards; C Banfield; J Lim; M Laughlin
Journal:  Eur J Pharm Sci       Date:  2004-04       Impact factor: 4.384

View more
  2 in total

Review 1.  Aspergillus fumigatus in the cystic fibrosis lung: pros and cons of azole therapy.

Authors:  Pierre-Régis Burgel; André Paugam; Dominique Hubert; Clémence Martin
Journal:  Infect Drug Resist       Date:  2016-09-20       Impact factor: 4.003

2.  An epidemic of iatrogenic Cushing's syndrome in anticipation in post-COVID era.

Authors:  Subhankar Chatterjee; Ritwik Ghosh; Bhagya Vardhan; Umesh Kumar Ojha; Sanjay Kalra
Journal:  J Family Med Prim Care       Date:  2022-01-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.